EHA 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

EHA 2022 Conference Coverage

Benign Hematology
Myeloma
Lymphoma
Leukemia
MDS and MPN

Playback speed

10 seconds

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated HR-MDS: 5F9005 Phase 1b Study Results

By EHA 2022 Conference Coverage FEATURING Uwe Platzbecker

17 views

June 21, 2022

Comments 0

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

MDS and MPN

Lecture Summary - EHA 2022 CD47 Targeting in HR-MDS: Surveying Clini…

EHA 2022 Conference Coverage

D. Sallman

24 views

EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magro…

EHA 2022 Conference Coverage

D. Sallman

399 views

EHA 2022 Conference Coverage

[private] Lecture Summary - EHA 2022 on ENHANCE Study: A Randomized …

Feat. D. Sallman

06:24

EHA 2022 Conference Coverage

[private] EHA 2022 on ENHANCE Study: A Randomized Phase 3 Study on M…

Feat. D. Sallman

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Hi…

EHA 2022 Conference Coverage

D. Sallman

255 views

Lecture Summary - EHA 2022 Magrolimab in Combination With Azacitidin…

EHA 2022 Conference Coverage

D. Sallman

14 views

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated HR…

EHA 2022 Conference Coverage

U. Platzbecker

17 views